Study: NCT03643276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Experimental therapy in randomizations R-HR and R-MR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Experimental therapy in randomizations R-HR and R-MR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Experimental therapy in randomizations R-HR and R-MR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Experimental therapy in randomizations R-HR and R-MR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Experimental therapy in randomization R-eHR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Experimental therapy in randomization R-eHR

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk